Atrium Therapeutics, Inc.
RNA
$12.69
$0.373.00%
NASDAQ
| 12/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 859.00K | 2.97M | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 859.00K | 2.97M | |||
| Cost of Revenue | 14.29M | 7.52M | |||
| Gross Profit | -13.43M | -4.55M | |||
| SG&A Expenses | 15.67M | 1.71M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.96M | 9.22M | |||
| Operating Income | -29.10M | -6.25M | |||
| Income Before Tax | -29.10M | -6.25M | |||
| Income Tax Expenses | 34.00K | 5.27M | |||
| Earnings from Continuing Operations | -29.14M | -11.51M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.14M | -11.51M | |||
| EBIT | -29.10M | -6.25M | |||
| EBITDA | -28.98M | -6.19M | |||
| EPS Basic | -1.88 | -- | |||
| Normalized Basic EPS | -1.17 | -- | |||
| EPS Diluted | -1.88 | -- | |||
| Normalized Diluted EPS | -1.17 | -- | |||
| Average Basic Shares Outstanding | 15.52M | -- | |||
| Average Diluted Shares Outstanding | 15.52M | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||